Good news from Guangdong inter provincial drug purchasing alliance
2021-12-11 12:32:36
The inter provincial drug procurement alliance led by Guangdong Province covers Guangdong, Shanxi, Henan, Hunan, Guangxi, Xinjiang and other provinces. It is one of the largest local centralized procurement alliances at present. This time, the Guangdong alliance purchases in quantity, and patients in the provinces within the alliance will be able to use high-quality original drugs at preferential prices to meet the growing demand for chronic disease treatment.
Professor Dong Yugang, director of cardiovascular medicine department of the First Affiliated Hospital of Sun Yat sen University, pointed out: "The centralized purchase of drugs has brought tangible benefits to the people, so that patients can afford and buy high-quality drugs. This time, the original clopidogrel and the original irbesartan hydrochlorothiazide have been successfully included in the list, which provides an effective guarantee for the majority of patients with cardiovascular diseases. While strengthening the medication compliance of patients, it improves the accessibility and safety of drugs, which will help to slow down the process Standardized management of diseases. "
Clopidogrel is used for myocardial infarction, ischemic stroke, peripheral arterial disease and acute coronary syndrome (ACS) Irbesartan hydrochlorothiazide is used for the treatment of essential hypertension. It is also a drug in the field of cardiovascular diseases. Its successful inclusion in the list will improve the drug availability of patients with cardiovascular diseases in Guangdong alliance and further help patients obtain the guarantee of standardized drug use and disease management.
Liu Jing, general manager of Sanofi China Innovation and core business department, said: "For nearly 40 years, Sanofi has always adhered to the concept of patient-centered and guaranteed the health of the Chinese people with high-quality drugs and services. We have been actively responding to relevant national policies and committed to enabling more Chinese patients to benefit from high-quality innovative drugs, providing sufficient guarantee for the standardized treatment of chronic diseases and helping to achieve 'Healthy China 2030'."
